Lauren C. Pinter-Brown

•Health Sciences Clinical Professor, Step 8, Division of Hematology/Oncology, Department of Medicine, UC Irvine

•Director, Cutaneous Lymphoma Program, UC-Irvine

Biography

Lauren C. Pinter-Brown, M.D., F.A.C.P., is Health Sciences Clinical Professor, Step 8, in the Division of Hematology/Oncology, Department of Medicine at UC Irvine, where she also serves as Director of the Cutaneous Lymphoma Program. She received her M.D. from UCLA School of Medicine in 1980 and completed her fellowship in hematology-oncology at LAC/USC Medical Center. Pinter-Brown has served as an independent investigator for the National Cancer Institute since 1986 and has been principal investigator on more than 60 clinical trials focused on lymphomas, particularly cutaneous and peripheral T-cell lymphomas.

Pinter-Brown is a Fellow of the American College of Physicians and serves on the Board of Directors of the International Society of Cutaneous Lymphoma. She has held leadership positions including Director of the Lymphoma Program at UCLA (2005-2012), Chairperson of the North American Educational Forum on Lymphoma for the Lymphoma Research Foundation (2010-2011), and Board Member of the United States Cutaneous Lymphoma Consortium (2009-2017) and Cutaneous Lymphoma Foundation (2013-2023). She has been a member of the Steering Committee for the Peripheral T-Cell Lymphoma International Registry since 2009 and served on the NCI Subcommittee for T-Cell Lymphoma of the Lymphoma Working Group (2010-2017).

Pinter-Brown has authored over 65 peer-reviewed research papers and multiple book chapters on lymphomas. She serves as a reviewer for numerous journals including Blood, Journal of Clinical Oncology, New England Journal of Medicine, and Lancet Haematology. Her research contributions include participation in pivotal trials that led to FDA approvals of therapies for cutaneous T-cell lymphoma and peripheral T-cell lymphoma, and she co-chaired the 2019 USCLC/Duke Think Tank on Clinical Trial Guidelines for Primary Cutaneous Lymphomas.

Return to top

Education

B.A., Brandeis University, 1976
M.D., UCLA School of Medicine, 1980

Return to top

Distinctions

Fellow, American College of Physicians, 1995
Award of Recognition, American Cancer Society, 1992
Los Angeles Super Doctors, 2007
Southern California Super Doctors, 2008-2009, 2012-2025
Orange County Medical Association Physicians of Excellence Honor, 2023-2025
UCI Health Patient Experience Award, 2017, 2023
Certificate of Appreciation, Olive View-UCLA Medical Center Health Services Improvement Program, 1992
Productivity and Quality Awareness Award, County of Los Angeles Department of Health Services, 1992
Award of Excellence in Small Group Instruction, Year II Blood Course, University of Southern California, 1988

Return to top

Areas of Expertise

Hematologic Malignancies
Cutaneous T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Hodgkin Disease Therapy
Mogamulizumab Clinical Trials
Brentuximab Vedotin Efficacy
Pralatrexate Treatment Outcomes

Recent Publications

Brazel D, Grant C, Cabal A, Chen WP, Pinter-Brown L, “Baseline immunoglobulin G and immune function in Non-Hodgkin lymphoma: a retrospective analysis” (opens in new tab), Frontiers in Immunology, vol. 15, pp. 1334899, 2024.
Mehta-Shah N, Zinzani PL, Jacobsen ED, Zain J, Mead M, Casulo C, Gritti G, Pinter-Brown LC, “Duvelisib I Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial”, Blood, vol. 144, no. Supplement 1, pp. 3061, 2024.
Querfeld C, Scarisbrick JJ, Akilov O, Arora P, Liu Y, Bagot M, Cordoba R, Cowan R, Garcia-Sancho AM, Geskin L, Huen AO, Jadwani J, Morris S, Ortiz-Romero PL, Patel AP, Pinter-Brown LC, “Mogamulizumab in Patients with Mycosis Fungoides/Sezary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule”, Blood, vol. 144, no. Supplement 1, pp. 3056, 2024.
Feldman T, Marchi E, Smith SD, Olszewski AJ, Huen AO, Epstein-Peterson ZD, Stevens DA, Starodub AN, Feldman EJ, Rodriguez CP, Reneau JC, Brammer JE, Mattour AH, Pinter-Brown LC, “Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia and Solid Tumors”, Blood, vol. 144, no. Supplement 1, pp. 4433, 2024.
Hu B, Nastoupil LJ, Holmes H, Hamdan A, Kanate A, Farooq U, Cherry M, Brem E, Pinter-Brown LC, “A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial”, Journal of Clinical Oncology, vol. 42, no. 16 suppl, pp. 7025, 2024.
Quaglino P, Scarisbrick J, Roccuzzo G, Abeldano A, Battistella M, McCormack C, Cowan R, Cozzio A, Cury-Martins J, Enz P, Geskin L, Guenova E, Kim YH, Knobler R, Litvinov IV, Miyagaki T, Molgo M, Nicolay J, Papadavid E, Pinter-Brown L, “Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey” (opens in new tab), Journal of the European Academy of Dermatology and Venereology, vol. 37, no. 4, pp. 680-688, 2023.
Brazel D, Pinter-Brown L, “SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL” (opens in new tab), Clinical Lymphoma Myeloma and Leukemia, vol. 23, no. 6, pp. 401-409, 2023.
Kincaid CM, Sharma AN, Lee BA, Pinter-Brown LC, “Alopecia Areata-like Presentations with Mogagmulizumab therapy” (opens in new tab), Jaad Case Reports, vol. 41, pp. 71-74, 2023.
Diefenbach, CS, Caimi, PF, Safa, NS, Vargas Madueno, F, Hamadani, M, Fayad, LE, Riedell, PA, Gillis-Smith, A, Simko, S, Orellana-Noia, V, Filippou-Frye, M, Kapp, AV, Relf, J, Lundberg, L, Pinter-Brown, LC, “Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase 1b Study” (opens in new tab), Blood, vol. 144, no. Supplement 1, pp. 987, 2023.
Grant C, Brazel D, Pinter-Brown LC, “Baseline Immunoglobulin G and Immune Function in Lymphoma: A Retrospective Analysis”, Blood, vol. 142, no. Supplement 1, pp. 1749, 2023.
Brem EA, O'Brien SM, Becker PS, Jeyakumar D, Pinter-Brown LC, “A Phase 1 Study of Adding Pitavastatin to Venetoclax-Based Therapy in AML and CLL/SLL”, Blood, vol. 142, no. Supplement 1, pp. 5940, 2023.
Shastri A, Feldman EJ, Starodub AN, Feldman T, Rodriguez CP, Epstein-Peterson ZD, Stevens DA, Olszewski AJ, Huen AO, Porcu P, Reneau JC, Barta SK, Marchi E, Mattour AH, Pinter-Brown LC, “Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors”, Blood, vol. 142, no. Supplement 1, pp. 3081, 2023.
Pinter-Brown LC, “Advances in the classification and management of patients with T-cell lymphoma”, Clinical Advances in Hematology and Oncology, vol. 20, no. 10, pp. 591-591, 2022.
Khanal R, Saultz JN, Farooq U, Nathan S, Mehta A, Hamdan A, Morris LE, Houston H, Pinter-Brown LC, “Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, as Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma”, Blood, vol. 140, no. Supplement 1, pp. 12742-12743, 2022.
Evans MG, Rezk SA, Pinter-Brown LC, Zhao X, “Aggressive CD5-Positive Primary Bone Marrow Diffuse Large B-Cell Lymphoma with Leukemic Presentation” (opens in new tab), Case Rep Hematol, vol. 2021, pp. 2628100, 2021.

Return to top

Most Cited Publications

Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW, “Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management” (opens in new tab), Journal of the American Academy of Dermatology, vol. 56, no. 2, pp. 317-26, 2007.
Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman M, Ballerini R, Liu L, Kim YH, “Phase1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma” (opens in new tab), Blood, vol. 125, no. 12, pp. 1883-9, 2015.
Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govindarajan S, “Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B” (opens in new tab), Cancer, vol. 65, no. 4, pp. 878-84, 1990.
Johnston PB, Pinter-Brown LC, Warsi G, White K, Ramchandren R, “Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma” (opens in new tab), Experimental Hematology and Oncology, vol. 7, pp. 12, 2018.
Chandrasoma P, Shibata D, Radin R, Brown LP, Koss M, “Malignant peripheral nerve sheath tumor arising in an adrenal ganglioneuroma in an adult male homosexual” (opens in new tab), Cancer, vol. 57, no. 10, pp. 2022-5, 1986.
Andorsky DJ, Cohen M, Naeim A, Pinter-Brown L, “Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over” (opens in new tab), Bone Marrow Transplantation, vol. 46, no. 9, pp. 1219-25, 2011.
Han K, Haley JC, Carlson K, Pinter-Brown L, Soriano T, “Regression of cutaneous intravascular lymphoma with rituximab”, Cutis, vol. 72, no. 2, pp. 137-40, 2003.
Evans MG, Miranda RN, Young PA, Pai L, Wang HY, Konoplev SN, Medeiros LJ, Pinter-Brown LC, “B-cell lymphomas associated with breast implants: Report of three cases and review of the literature” (opens in new tab), Annals of Diagnostic Pathology, vol. 46, pp. 151512, 2020.
Blackmon AL, Pinter-Brown L, “Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection” (opens in new tab), Drug Design Development and Therapy, vol. 14, pp. 3747-3754, 2020.
Alamdari HS, Pinter-Brown L, Cassarino DS, Chiu M, “Severe cutaneous interface drug eruption associated with bendamustine”, Dermatology Online Journal, vol. 16, no. 7, pp. 1, 2010.

Return to top

Contact Information

Email: lpinterb@uci.edu

Phone: (714) 456-5153

Address: 101 City Drive South, Bldg 56, Rm 232, Irvine, CA 92697-4061

Return to top

This profile was created with the help of AI.

Last updated on 3/13/2026.